Literature DB >> 25595786

PTEN is a negative regulator of NK cell cytolytic function.

Edward L Briercheck1, Rossana Trotta2, Li Chen3, Alex S Hartlage1, Jordan P Cole3, Tyler D Cole3, Charlene Mao3, Pinaki P Banerjee4, Hsiang-Ting Hsu5, Emily M Mace5, David Ciarlariello6, Bethany L Mundy-Bosse3, Isabel Garcia-Cao7, Steven D Scoville1, Lianbo Yu8, Robert Pilarski9, William E Carson10, Gustavo Leone11, Pier Paolo Pandolfi12, Jianhua Yu13, Jordan S Orange4, Michael A Caligiuri14.   

Abstract

Human NK cells are characterized by their ability to initiate an immediate and direct cytolytic response to virally infected or malignantly transformed cells. Within human peripheral blood, the more mature CD56(dim) NK cell efficiently kills malignant targets at rest, whereas the less mature CD56(bright) NK cells cannot. In this study, we show that resting CD56(bright) NK cells express significantly more phosphatase and tensin homolog deleted on chromosome 10 (PTEN) protein when compared with CD56(dim) NK cells. Consistent with this, forced overexpression of PTEN in NK cells resulted in decreased cytolytic activity, and loss of PTEN in CD56(bright) NK cells resulted in elevated cytolytic activity. Comparable studies in mice showed PTEN overexpression did not alter NK cell development or NK cell-activating and inhibitory receptor expression yet, as in humans, did decrease expression of downstream NK activation targets MAPK and AKT during early cytolysis of tumor target cells. Confocal microscopy revealed that PTEN overexpression disrupts the NK cell's ability to organize immunological synapse components including decreases in actin accumulation, polarization of the microtubule organizing center, and the convergence of cytolytic granules. In summary, our data suggest that PTEN normally works to limit the NK cell's PI3K/AKT and MAPK pathway activation and the consequent mobilization of cytolytic mediators toward the target cell and suggest that PTEN is among the active regulatory components prior to human NK cells transitioning from the noncytolytic CD56(bright) NK cell to the cytolytic CD56(dim) NK cells.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25595786      PMCID: PMC4319309          DOI: 10.4049/jimmunol.1401224

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Authors:  T A Fehniger; M H Shah; M J Turner; J B VanDeusen; S P Whitman; M A Cooper; K Suzuki; M Wechser; F Goodsaid; M A Caligiuri
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

2.  miR-155 regulates IFN-γ production in natural killer cells.

Authors:  Rossana Trotta; Li Chen; David Ciarlariello; Srirama Josyula; Charlene Mao; Stefan Costinean; Lianbo Yu; Jonathan P Butchar; Susheela Tridandapani; Carlo M Croce; Michael A Caligiuri
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

3.  The Pten/PI3K pathway governs the homeostasis of Valpha14iNKT cells.

Authors:  Hiroyuki Kishimoto; Toshiaki Ohteki; Nobuyuki Yajima; Koichi Kawahara; Miyuki Natsui; Satoru Kawarasaki; Koichi Hamada; Yasuo Horie; Yoshiaki Kubo; Seiji Arase; Masaru Taniguchi; Bart Vanhaesebroeck; Tak Wah Mak; Toru Nakano; Shigeo Koyasu; Takehiko Sasaki; Akira Suzuki
Journal:  Blood       Date:  2006-12-14       Impact factor: 22.113

4.  RNA trafficking by acute myelogenous leukemia exosomes.

Authors:  Jianya Huan; Noah I Hornick; Matthew J Shurtleff; Amy M Skinner; Natalya A Goloviznina; Charles T Roberts; Peter Kurre
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

5.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

Authors:  A Suzuki; M T Yamaguchi; T Ohteki; T Sasaki; T Kaisho; Y Kimura; R Yoshida; A Wakeham; T Higuchi; M Fukumoto; T Tsubata; P S Ohashi; S Koyasu; J M Penninger; T Nakano; T W Mak
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

6.  Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases.

Authors:  J Liliental; S Y Moon; R Lesche; R Mamillapalli; D Li; Y Zheng; H Sun; H Wu
Journal:  Curr Biol       Date:  2000-04-06       Impact factor: 10.834

7.  MicroRNAs activate natural killer cells through Toll-like receptor signaling.

Authors:  Shun He; Jianhong Chu; Lai-Chu Wu; Hsiaoyin Mao; Yong Peng; Christopher A Alvarez-Breckenridge; Tiffany Hughes; Min Wei; Jianying Zhang; Shunzong Yuan; Sumeet Sandhu; Sumithira Vasu; Don M Benson; Craig C Hofmeister; Xiaoming He; Kalpana Ghoshal; Steven M Devine; Michael A Caligiuri; Jianhua Yu
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

Review 8.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

9.  CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.

Authors:  Jianhua Yu; Hsiaoyin C Mao; Min Wei; Tiffany Hughes; Jianying Zhang; Il-kyoo Park; Shujun Liu; Susan McClory; Guido Marcucci; Rossana Trotta; Michael A Caligiuri
Journal:  Blood       Date:  2009-11-06       Impact factor: 22.113

10.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

Authors:  Stephan Sauer; Ludovica Bruno; Arnulf Hertweck; David Finlay; Marion Leleu; Mikhail Spivakov; Zachary A Knight; Bradley S Cobb; Doreen Cantrell; Eric O'Connor; Kevan M Shokat; Amanda G Fisher; Matthias Merkenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-28       Impact factor: 11.205

View more
  22 in total

Review 1.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 2.  Immunometabolism of T cells and NK cells: metabolic control of effector and regulatory function.

Authors:  Sophie M Poznanski; Nicole G Barra; Ali A Ashkar; Jonathan D Schertzer
Journal:  Inflamm Res       Date:  2018-07-31       Impact factor: 4.575

3.  Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Authors:  Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra
Journal:  Blood Adv       Date:  2018-08-14

4.  Mutations in PI3K110δ cause impaired natural killer cell function partially rescued by rapamycin treatment.

Authors:  Raquel Ruiz-García; Alexander Vargas-Hernández; Ivan K Chinn; Laura S Angelo; Tram N Cao; Zeynep Coban-Akdemir; Shalini N Jhangiani; Qingchang Meng; Lisa R Forbes; Donna M Muzny; Luis M Allende; Mohammed S Ehlayel; Richard A Gibbs; James R Lupski; Gulbu Uzel; Jordan S Orange; Emily M Mace
Journal:  J Allergy Clin Immunol       Date:  2018-01-10       Impact factor: 10.793

5.  Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.

Authors:  Aaron R Victor; Christoph Weigel; Steven D Scoville; Wing Keung Chan; Kelsey Chatman; Mary M Nemer; Charlene Mao; Karen A Young; Jianying Zhang; Jianhua Yu; Aharon G Freud; Christopher C Oakes; Michael A Caligiuri
Journal:  J Immunol       Date:  2017-12-11       Impact factor: 5.422

6.  Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.

Authors:  Jessica Wagner; C Leah Kline; Lanlan Zhou; Kerry S Campbell; Alexander W MacFarlane; Anthony J Olszanski; Kathy Q Cai; Harvey H Hensley; Eric A Ross; Marie D Ralff; Andrew Zloza; Charles B Chesson; Jenna H Newman; Howard Kaufman; Joseph Bertino; Mark Stein; Wafik S El-Deiry
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

7.  Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function.

Authors:  Steven D Scoville; Ansel P Nalin; Luxi Chen; Li Chen; Michael H Zhang; Kathleen McConnell; Susana Beceiro Casas; Gabrielle Ernst; Abd Al-Rahman Traboulsi; Naima Hashi; Monica Williams; Xiaoli Zhang; Tiffany Hughes; Anjali Mishra; Don M Benson; Jennifer N Saultz; Jianhua Yu; Aharon G Freud; Michael A Caligiuri; Bethany L Mundy-Bosse
Journal:  Blood       Date:  2018-08-29       Impact factor: 22.113

8.  A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets.

Authors:  Steven D Scoville; Bethany L Mundy-Bosse; Michael H Zhang; Li Chen; Xiaoli Zhang; Karen A Keller; Tiffany Hughes; Luxi Chen; Stephanie Cheng; Stephen M Bergin; Hsiaoyin C Mao; Susan McClory; Jianhua Yu; William E Carson; Michael A Caligiuri; Aharon G Freud
Journal:  Immunity       Date:  2016-05-10       Impact factor: 31.745

9.  Measurement of Lytic Granule Convergence After Formation of an NK Cell Immunological Synapse.

Authors:  Hsiang-Ting Hsu; Alexandre F Carisey; Jordan S Orange
Journal:  Methods Mol Biol       Date:  2017

10.  CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

Authors:  Julia A Wagner; Maximillian Rosario; Rizwan Romee; Melissa M Berrien-Elliott; Stephanie E Schneider; Jeffrey W Leong; Ryan P Sullivan; Brea A Jewell; Michelle Becker-Hapak; Timothy Schappe; Sara Abdel-Latif; Aaron R Ireland; Devika Jaishankar; Justin A King; Ravi Vij; Dennis Clement; Jodie Goodridge; Karl-Johan Malmberg; Hing C Wong; Todd A Fehniger
Journal:  J Clin Invest       Date:  2017-10-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.